Novo Nordisk Valuation
| N1VO34 Stock | BRL 76.51 2.18 2.93% |
At this time, the firm appears to be overvalued. Novo Nordisk AS secures a last-minute Real Value of R$71.73 per share. The latest price of the firm is R$76.51. Our model forecasts the value of Novo Nordisk AS from analyzing the firm fundamentals such as Profit Margin of 0.31 %, current valuation of 1.59 T, and Return On Equity of 0.72 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Novo Nordisk's price fluctuation is very steady at this time. Calculation of the real value of Novo Nordisk AS is based on 3 months time horizon. Increasing Novo Nordisk's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Novo Nordisk is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novo Stock. However, Novo Nordisk's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 76.51 | Real 71.73 | Hype 76.51 | Naive 76.27 |
The real value of Novo Stock, also known as its intrinsic value, is the underlying worth of Novo Nordisk AS Company, which is reflected in its stock price. It is based on Novo Nordisk's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Novo Nordisk's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Novo Nordisk AS helps investors to forecast how Novo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novo Nordisk more accurately as focusing exclusively on Novo Nordisk's fundamentals will not take into account other important factors: Novo Nordisk Total Value Analysis
Novo Nordisk AS is now anticipated to have takeover price of 1.59 T with market capitalization of 1.67 T, debt of 9.65 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Novo Nordisk fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.59 T | 1.67 T | 9.65 B |
Novo Nordisk Investor Information
The book value of the company was now reported as 37.1. The company has Price/Earnings To Growth (PEG) ratio of 0.25. Novo Nordisk AS recorded earning per share (EPS) of 18.22. The entity last dividend was issued on the 24th of March 2023. The firm had 1:2 split on the 18th of September 2023. Based on the analysis of Novo Nordisk's profitability, liquidity, and operating efficiency, Novo Nordisk AS is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Novo Nordisk Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novo Nordisk has an asset utilization ratio of 72.39 percent. This suggests that the Company is making R$0.72 for each dollar of assets. An increasing asset utilization means that Novo Nordisk AS is more efficient with each dollar of assets it utilizes for everyday operations.Novo Nordisk Profitability Analysis
The company reported the revenue of 140.8 B. Net Income was 47.76 B with profit before overhead, payroll, taxes, and interest of 148.51 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novo Nordisk's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novo Nordisk and how it compares across the competition.
About Novo Nordisk Valuation
The stock valuation mechanism determines Novo Nordisk's current worth on a weekly basis. Our valuation model uses a comparative analysis of Novo Nordisk. We calculate exposure to Novo Nordisk's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novo Nordisk's related companies.8 Steps to conduct Novo Nordisk's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novo Nordisk's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novo Nordisk's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novo Nordisk's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novo Nordisk's revenue streams: Identify Novo Nordisk's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novo Nordisk's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novo Nordisk's growth potential: Evaluate Novo Nordisk's management, business model, and growth potential.
- Determine Novo Nordisk's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novo Nordisk's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |